Clinical trials: Malignancies Multiple
Prostate Cancer Patients, Sexual Dysfunctions
Dyadic STEP-SexPCare for Sexual Health in Chinese Prostate Cancer Survivors and Their Female Partners
This pilot feasibility randomized controlled trial will evaluate the feasibility, acceptability, safety, and preliminary effects of Dyadic STEP-SexPCare, a culturally tailored, nurse-led psychosexual programme for Hong Kong…
- Trial name
- STEP-SexPCare (NCT07829367)
- Testing
- Dyadic STEP-SexPCare, Standard Survivorship Care
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Solid Tumour Neoplastic Meningitis, Brain Metastases
Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.
The purpose of this study is to demonstrate the safety of giving Whole Brain Radiotherapy (WBRT) together with intrathecal liposomal cytarabine (DepoCyte®) for patients with leptomeningeal metastases.
- Trial name
- NCT00854867
- Testing
- Whole Brain Radio Therapy (WBRT) with sequential Depocyte, Whole brain radiotherapy (WBRT) with concomitant Depocyte
- Where
- 7 sites in Austria, Germany
- Volunteers
- 18 people
- Sponsor
- Mundipharma Research Limited
Radiotherapy, PD-1 Inhibitor
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal…
- Conditions
- Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma
- Trial name
- NCT05290194
- Testing
- SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Capecitabine
- Where
- China
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Ph+ ALL, Bone Marrow Transplant
A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive
Hematopoietic stem cell transplantation (HSCT) is the effective and even the only cure treatment option for ph+ acute lymphocyte leukemia (ph+ALL).
- Conditions
- Ph+ ALL, Bone Marrow Transplant, Minimal Residual Disease
- Trial name
- NCT05603156
- Testing
- the usage of Olverembatinib combined with Inotuzumab Ozogamicin
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Lynch Syndrome, Li Fraumeni Syndrome
Video Capsule Examination in Patients With Lynch Syndrome
Surveillance for colorectal cancer (CRC) in patients predisposed to develop CRC during their lifetime has been impacted by access to colonoscopy suites and endoscopy specialists in the past couple of years.
- Conditions
- Lynch Syndrome, Li Fraumeni Syndrome, PTEN Hamartoma Syndrome, FAP
- Trial name
- PILLCAM (NCT06712095)
- Testing
- Video capsule investigation
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
TNBC, Triple Negative Breast Cancer
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of Adjuvant treatment of TNBC breast cancer with Toripalimab combined…
- Trial name
- NCT06682195
- Testing
- Neoadjuvant chemotherapy combined with Toripalimab
- Where
- 13 sites in China
- Volunteers
- 35 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Multiple Myeloma
Velcade Consolidation Bone Study
The purpose of this study is to assess the effect of bortezomib on myeloma-related bone disease, analyzing bone mineral density (BMD) in patients with Multiple Myeloma (MMY) who have received high dose chemotherapy and autologous…
- Trial name
- NCT01286077
- Testing
- bortezomib
- Where
- 21 sites in Austria, Czechia and 6 more
- Volunteers
- 106 people
- Sponsor
- Janssen-Cilag International NV
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and immune molecules attack the nervous system as the main…
- Conditions
- Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis
- Trial name
- CARTinNS (NCT04561557)
- Testing
- CT103A cells, Cyclophosphamide and fludarabine
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tongji Hospital
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Advanced Cancer
Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer
After the fourth protocol amendment two study arms are evaluated in this clinical protocol: PD-0325901 (oral MEK inhibitor) plus PF-05212384 (intravenous PI3K/mTOR inhibitor) and PF-05212384 plus irinotecan.
- Trial name
- NCT01347866
- Testing
- PF-05212384, PD-0325901, irinotecan
- Where
- 18 sites in United States, Canada and 2 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
Breast Neoplasms
A Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer
Multi-center, open-label, randomized trial of patients with low-risk, HER2+ disease, who will receive adjuvant taxane-based chemotherapy (i.e.
- Trial name
- NCT03705429
- Testing
- TC-H x Paclitaxel (P) + Trastuzumab(T)
- Where
- 3 sites in Canada
- Volunteers
- 51 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Multiple Myeloma
Role of18F-FDG PET-CT for Assessing and Predicting Response to Daratumumab and for Prognosis With Multiple Myeloma
Positron Emission Tomography - Computed Tomography (PET-CT) using fluorine-18 fluorodeoxyglucose is a functional imaging diagnostic tool which is widely used In several neoplastic conditions, at initial staging, for restaging in…
- Trial name
- NCT06170151
- Testing
- Diagnostic accuracy
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- IRCCS San Raffaele
Prostatic Neoplasms, Psychological Distress
ComCancer: Use of Let's Discuss Health Website by Patients With Prostate Cancer Undergoing Radiation Oncology Treatment
In Canada, the prevalence of cancer is growing and contributes significantly to health costs. The prevention and treatment of cancer is a major concern of our health system.
- Conditions
- Prostatic Neoplasms, Psychological Distress, Physician-Patient Relations, Communication
- Trial name
- NCT05787145
- Testing
- Let's Discuss Health Group
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Sarcoma
Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma
The purpose is to evaluate the effectiveness and safety of Surufatinib in patients with osteosarcoma and soft tissue sarcoma after Standard chemotherapy therapy.
- Trial name
- NCT05106777
- Testing
- Surufatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Safety Issues, Tolerability
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
This is a Phase 1/2a first-in-human, multi-center, non-randomized, open-label study to assess the safety, tolerability, pharmacokinetics profile, and preliminary anti-tumor activity of IPG7236 administered orally as a single…
- Conditions
- Safety Issues, Tolerability, Pharmacokinetics
- Trial name
- NCT05142592
- Testing
- IPG7236
- Where
- 7 sites in United States, China
- Volunteers
- 34 people
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd
Multiple Myeloma
Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma
Prospective, single center, randomized, open label, parallel group, 2-arm study assessing the clinical benefit in term of enhancement of overall response rate of Isatuximab in combination with CellProtect as compared to…
- Trial name
- NCT04558931
- Testing
- CellProtect, Isatuximab
- Where
- Sweden
- Volunteers
- 62 people
- Sponsor
- Karolinska Institutet
Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer
Local Liver Treatment for Multi-organ Colorectal Cancer Metastases
The purpose of this study was to investigate the effect of only local radical treatment of liver metastases combined with systematic treatment in the treatment of patients with multiple organ metastases of colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Multi-organ Metastatic Colorectal Cancer, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT06449937
- Testing
- Radical local Surgery, Systemic therapy, Interventional therapy
- Where
- 6 sites in China
- Volunteers
- 130 people
- Sponsor
- Anhui Provincial Hospital
Breast Cancer, Lung Cancer
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
The Carevive registry collects patient characteristics, patient symptoms, and treatment experience data from patients receiving cancer treatment for breast, lung, GI or multiple myeloma.
- Conditions
- Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Multiple Myeloma
- Trial name
- NCT05587972
- Testing
- survey
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Carevive Systems, Inc.
Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
The purpose of this study to find out whether codrituzumab is a safe treatment that causes few or mild side effects in children and young adults who have solid tumors that express the protein GPC3.
- Trial name
- NCT04928677
- Testing
- Codrituzumab
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a…
- Trial name
- NCT04786028
- Testing
- Isatuximab
- Where
- 7 sites in Canada
- Volunteers
- 72 people
- Sponsor
- Canadian Myeloma Research Group